The treatment involves receiving blinatumomab, which is a medication given as an injection under the skin. This medication is designed to help the immune system fight leukemia cells.

The treatment is organized into cycles, which are repeated time periods during which the medication is given. The specific dosage and schedule will be determined based on individual circumstances and the phase of the study.

During the first 2 cycles, the medical team will closely monitor the response to treatment. Each cycle typically involves a period of medication administration followed by a break.

Throughout the treatment, regular assessments will be conducted to monitor how the body is responding to the medication.

Blood samples will be collected to measure the levels of medication in the bloodstream and to check for any signs of improvement in the condition.

Bone marrow samples may be taken to assess the number of leukemia cells remaining. The goal is to reduce the level of disease to less than 0.01%, which is considered a negative response for minimal residual disease.

The medical team will monitor for any side effects or adverse reactions to the medication throughout the treatment period.

After completing the first 2 cycles of treatment, a comprehensive evaluation will be performed to determine how well the treatment is working.

For participants with relapsed or refractory disease, the evaluation will focus on whether complete remission has been achieved, meaning that leukemia cells are no longer detectable in the bone marrow at significant levels.

For participants with minimal residual disease positive status at the start, the evaluation will assess whether the disease has been reduced to undetectable levels.

The results of these evaluations will help determine the next steps in the treatment plan.

Based on the response to the initial cycles, additional cycles of blinatumomab treatment may be administered.

The duration of continued treatment will depend on individual response and tolerability of the medication.

Throughout all treatment cycles, ongoing monitoring for side effects and treatment effectiveness will continue.

After completing the treatment cycles, regular follow-up visits will be scheduled to monitor long-term outcomes.

These visits will include assessments to check whether the disease remains in remission and to monitor overall health status.

The medical team will track the duration of response, which is the length of time from achieving remission until any signs of disease return or until any other significant health event occurs.

Blood tests will be performed to check for the development of antibodies against the medication, which could affect how the body responds to treatment.